Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31158206 | 1.00 | ALDH1A1 (0.55) | ALDH1A1MAPTRECQLPTGS2KDM4E | |
| SCHEMBL2736359 | 1.00 | ALDH1A1 (0.55) | ALDH1A1MAPTRECQLPTGS2KDM4E | |
| SCHEMBL1906547 | 1.00 | ALDH1A1 (0.55) | ALDH1A1MAPTRECQLPTGS2KDM4E | |
| Hydrochloric Acid SCHEMBL4700254 | 0.99 | ALDH1A1 (0.54) | ALDH1A1MAPTRECQLPTGS2KDM4E | |
| Hydrochloric Acid SCHEMBL27829206 | 0.99 | ALDH1A1 (0.54) | ALDH1A1MAPTRECQLPTGS2KDM4E | |
| Hydrochloric Acid SCHEMBL1710809 | 0.99 | ALDH1A1 (0.54) | ALDH1A1MAPTRECQLPTGS2KDM4E | |
| SCHEMBL21965973 | 0.89 | ALDH1A1 (0.55) | ALDH1A1MAPTRECQLPTGS2KDM4E | |
| SCHEMBL23677906 | 0.88 | ALDH1A1 (0.54) | ALDH1A1MAPTRECQLKDM4EGPR84 | |
| SCHEMBL18395823 | 0.88 | ALDH1A1 (0.54) | ALDH1A1MAPTRECQLKDM4EGPR84 | |
| SCHEMBL30584520 | 0.88 | ALDH1A1 (0.54) | ALDH1A1MAPTRECQLKDM4EGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486300-B2 | Mithramycin oxime derivatives having increased selectivity and anti-cancer activity | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2025-12-02 | — | — | US | disclosed |
| WO-2024081692-A1 | MITHRAMYCIN OXIME DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20230132854-A1 | MITHRAMYCIN OXIME DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2023-05-04 | — | — | US | disclosed |
| US-11485705-B2 | Salts and prodrugs of 1-methyl-d-tryptophan | LUMOS PHARMA, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| US-11466045-B2 | Mithramycin oxime derivatives having increased selectivity and anti-cancer activity | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2022-10-11 | — | — | US | disclosed |
| EP-3613420-B1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA INC (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3954369-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | Lumos Pharma, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3324958-B1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA INC (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20200283385-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2020-09-10 | — | — | US | disclosed |
| US-20200131218-A1 | MITHRAMYCIN OXIME AND HYDRAZINE DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2020-04-30 | — | — | US | disclosed |
| EP-3324958-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | Newlink Genetics Corporation (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20180134658-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2018-05-17 | — | — | US | disclosed |
| US-9732035-B2 | Salts and prodrugs of 1-methyl-D-tryptophan | NEWLINK GENETICS CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| WO-2017019175-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | NEWLINK GENETICS CORPORATION (US) | 2017-02-02 | — | — | WO | disclosed |
| US-20170022157-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2017-01-26 | — | — | US | disclosed |
| EP-2493862-B1 | IMIDAZOLE DERIVATIVES AS IDO INHIBITORS | NEWLINK GENETICS CORP (US) | 2016-10-05 | — | — | EP | disclosed |
| US-8722720-B2 | Imidazole derivatives as IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-05-13 | — | — | US | disclosed |
| US-20120277217-A1 | Imidazole Derivatives as IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2012-11-01 | — | — | US | disclosed |
| EP-2493862-A1 | IMIDAZOLE DERIVATIVES AS IDO INHIBITORS | Newlink Genetics Corporation (US) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011056652-A1 | IMIDAZOLE DERIVATIVES AS IDO INHIBITORS | NEWLINK GENETICS (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486300-B2 | Mithramycin oxime derivatives having increased selectivity and anti-cancer activity | TFAM, HSPE1, PRDX3 | ALDH1A1 2030/4885MAPT 577/4885RECQL 2216/4885 |
| US-11466045-B2 | Mithramycin oxime derivatives having increased selectivity and anti-cancer activity | HSPE1, TFAM, HMOX1 | ALDH1A1 1515/4885MAPT 597/4885RECQL 2443/4885 |
| US-20230132854-A1 | MITHRAMYCIN OXIME DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY | TFAM, HSPE1, PRDX3 | ALDH1A1 2030/4885MAPT 577/4885RECQL 2216/4885 |
| US-20200283385-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | IDO1, IDO2, INMT | ALDH1A1 634/4885MAPT 2135/4885RECQL 2301/4885 |
| US-11485705-B2 | Salts and prodrugs of 1-methyl-d-tryptophan | IDO1, IDO2, INMT | ALDH1A1 634/4885MAPT 2135/4885RECQL 2301/4885 |
| US-20170022157-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | IDO1, IDO2, INMT | ALDH1A1 634/4885MAPT 2135/4885RECQL 2301/4885 |
| US-20120277217-A1 | Imidazole Derivatives as IDO Inhibitors | IDO1, IDO2, INMT | ALDH1A1 705/4885MAPT 3332/4885RECQL 2409/4885 |
| US-20180134658-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | IDO1, IDO2, INMT | ALDH1A1 634/4885MAPT 2135/4885RECQL 2301/4885 |
| US-20200131218-A1 | MITHRAMYCIN OXIME AND HYDRAZINE DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY | HMOX1, HSPE1, TFAM | ALDH1A1 1340/4885MAPT 583/4885RECQL 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.